Skip to main navigation
Menu
Main navigation
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2025
GRx+Biosims 2024
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action
Search
Close
Breadcrumb
Association for Accessible Medicines
Resources
Resources
Share
Find up-to-date information on generics and biosimilars
Filter Resources
Issues
Biosimilar User Fee Act (BsUFA)
Biosimilars
Complex Generics
Drug Approval Process (GDUFA)
Drug Prices
Drug Shortages
Generic Drug Labeling
Generic Supply Chain
IP Issues
Low Income Subsidies (LIS in Part D)
Medicaid
Medicare
NAFTA
Patent Reform
Patient Stories
Pharmaceutical Waste Take Back
Preventing Drug Abuse
Quality
REMS/Sample Acquisition Remedies
State Initiatives
Tariffs
Trade
Transparency
User Fees
Resource Type
Blog
Amicus Brief
Press Release
Infographic
Video
Report
Fact Sheet
Presentation
Press Release
Jul 28, 2022
| Allen Goldberg
Association for Accessible Medicines (AAM) Elevates David Gaugh to Executive Vice President for Sciences & Regulatory Affairs
Blog
Jul 25, 2022
| Craig Burton
Drug Price Negotiation Proposals Undermine Current Bipartisan Approaches to Lower Drug Spending
Blog
Jul 21, 2022
| Dan Leonard
AAM All Access Podcast: CMMB’s Urgent Mission
Blog
Jul 20, 2022
| Craig Burton
The Evidence Is Clear: Biosimilar Competition Will Achieve More Savings for Patients Than Build Back Better’s Negotiations
Blog
Jul 20, 2022
| Craig Burton
Medicare Negotiations Serve as a Catalyst to a Perpetual Monopoly
Blog
Jul 20, 2022
| Craig Burton
Proposed BBB Negotiation Framework Discourages Biosimilar Competition, Imposes Higher Costs on Commercially Insured Patients and Their Employers
Blog
Jul 12, 2022
| Monét Stanford
Despite Enrollment In Medicare Prescription Drug Coverage, Over Half of All Seniors Pay Full Cost for Many Generic Drugs
Press Release
Jul 6, 2022
| Allen Goldberg
AAM Statement on BBB 2.0
Blog
Jul 1, 2022
| Dan Leonard
AAM All Access Podcast: Drug Shortages and the U.S. Supply Chain
Report
Jun 13, 2022
| Erica Klinger
AAM Code of Business Ethics
Fact Sheet
Jun 7, 2022
| Erica Klinger
The Hatch-Waxman 180-Day Exclusivity Incentive Accelerates Patient Access to First Generics
Press Release
Jun 6, 2022
| Allen Goldberg
Giuseppe Randazzo Joins AAM as Vice President, Sciences and Regulatory Affairs
Load More
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2025
GRx+Biosims 2024
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action